Lisata Therapeutics closes Marea Therapeutics merger and $225M private placement, with pro forma financials
Lisata Therapeutics completed its acquisition of Marea Therapeutics on September 17, 2026, issuing common stock and Series C Non-Voting Convertible Preferred Stock to Marea holders. A concurrent private placement of Series C preferred to institutional investors closed September 18 for about $225.0 million gross. Following stockholder approval and conversion, former Marea holders are expected to own about 59.5% of the combined company, PIPE investors about 38.1% and legacy Lisata holders about 2.4%; the filing presents unaudited pro forma combined financials.
Company's press release (SEC filing): Lisata Therapeutics, Inc. ↗
Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.
IndustryCompany releaseIM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
IndustryCompany releaseHelus Pharma, formerly Cybin, reports $150.9M six-month net loss as share compensation rises
IndustryCompany releaseIM Cannabis sells German arm to CEO-controlled Slil, refocusing on Israel
IndustryCompany releaseDataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
IndustryCompany releaseXenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient
IndustryCompany release